Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01700387 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
A Phase 4 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01700387 is a Phase 4 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 20 participants.
The verdict
NCT01700387, a Phase 4 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate sustained tolerability, quality of life, and change in cognitive efficiency following treatment with OnabotulinumtoxinA and daily topiramate vs. OnabotulinumtoxinA and daily placebo (Group A vs. Group B).
Interventions
- DRUG Placebo
- DRUG Topiramate
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01700387
The ClinicalTrials.gov registry entry for NCT01700387 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cady, Roger, M.D., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01700387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01700387 about?
NCT01700387 is a clinical study titled "A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency". The purpose of this study is to evaluate sustained tolerability, quality of life, and change in cognitive efficiency following treatment with OnabotulinumtoxinA and daily topiramate vs. OnabotulinumtoxinA and daily placebo (Group A vs. Group B).
What is the current status of trial NCT01700387?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2012-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01700387?
The interventions under investigation include: Placebo (DRUG), Topiramate (DRUG), onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT01700387?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.